Schering Gains HCV Retreatment Indication For Pegintron/Rebetol In EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Commission clears the combination to retreat adults whose prior treatment with interferon alpha and ribavirin did not result in a sustained response.
You may also be interested in...
Roche Polymerase Inhibitor Shows Promise In Phase II
Ahead of AASLD, Roche’s Senior Medical Director Thommes discusses the firm’s hepatitis C pipeline with “The Pink Sheet” DAILY.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.